» Articles » PMID: 21463522

Overall Asthma Control Achieved with Budesonide/formoterol Maintenance and Reliever Therapy for Patients on Different Treatment Steps

Overview
Journal Respir Res
Specialty Pulmonary Medicine
Date 2011 Apr 6
PMID 21463522
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Adjusting medication for uncontrolled asthma involves selecting one of several options from the same or a higher treatment step outlined in asthma guidelines. We examined the relative benefit of introducing budesonide/formoterol (BUD/FORM) maintenance and reliever therapy (Symbicort SMART® Turbuhaler®) in patients previously prescribed treatments from Global Initiative for Asthma (GINA) Steps 2, 3 or 4.

Methods: This is a post hoc analysis of the results of five large clinical trials (>12000 patients) comparing BUD/FORM maintenance and reliever therapy with other treatments categorised by treatment step at study entry. Both current clinical asthma control during the last week of treatment and exacerbations during the study were examined.

Results: At each GINA treatment step, the proportion of patients achieving target levels of current clinical control were similar or higher with BUD/FORM maintenance and reliever therapy compared with the same or a higher fixed maintenance dose of inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) (plus short-acting β2-agonist [SABA] as reliever), and rates of exacerbations were lower at all treatment steps in BUD/FORM maintenance and reliever therapy versus same maintenance dose ICS/LABA (P < 0.01) and at treatment Step 4 versus higher maintenance dose ICS/LABA (P < 0.001). BUD/FORM maintenance and reliever therapy also achieved significantly higher rates of current clinical control and significantly lower exacerbation rates at most treatment steps compared with a higher maintenance dose ICS + SABA (Steps 2-4 for control and Steps 3 and 4 for exacerbations). With all treatments, the proportion of patients achieving current clinical control was lower with increasing treatment steps.

Conclusions: BUD/FORM maintenance and reliever therapy may be a preferable option for patients on Steps 2 to 4 of asthma guidelines requiring a more effective treatment and, compared with other fixed dose alternatives, is most effective in the higher treatment steps.

Citing Articles

Patient response to the management during the acute presentation of cough variant Asthma: Retrospective cohort study.

Ibrahim Arif S, Amer Y, Adnan Alkamal T, Abdulrahman Binsaeed M, Ibrahim Arif B, Dhaifallah Albaqami M Saudi J Biol Sci. 2023; 30(12):103875.

PMID: 38058763 PMC: 10696240. DOI: 10.1016/j.sjbs.2023.103875.


Clinical standards for the diagnosis and management of asthma in low- and middle-income countries.

Jayasooriya S, Stolbrink M, Khoo E, Sunte I, Awuru J, Cohen M Int J Tuberc Lung Dis. 2023; 27(9):658-667.

PMID: 37608484 PMC: 10443788. DOI: 10.5588/ijtld.23.0203.


Summary of Korean Asthma Guideline.

Rhee C, Moon J, Joo H, Jung J, Lee J, Min K Tuberc Respir Dis (Seoul). 2023; 86(3):158-165.

PMID: 37254491 PMC: 10323208. DOI: 10.4046/trd.2023.0052.


Short-acting beta-2 agonist prescription patterns and clinical outcomes in Chinese patients with asthma: an observational study in mainland China for the SABINA programme.

Bao W, Zhang Y, Hang J, Guo Y, Tang W, Yun C Ther Adv Respir Dis. 2022; 16:17534666221115054.

PMID: 36065527 PMC: 9449520. DOI: 10.1177/17534666221115054.


Asthma management in low and middle income countries: case for change.

Mortimer K, Reddel H, Pitrez P, Bateman E Eur Respir J. 2022; 60(3).

PMID: 35210321 PMC: 9474897. DOI: 10.1183/13993003.03179-2021.


References
1.
Bateman E, Bousquet J, Busse W, Clark T, Gul N, Gibbs M . Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. Allergy. 2008; 63(7):932-8. DOI: 10.1111/j.1398-9995.2008.01724.x. View

2.
Bousquet J, Boulet L, Peters M, Magnussen H, Quiralte J, Martinez-Aguilar N . Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med. 2007; 101(12):2437-46. DOI: 10.1016/j.rmed.2007.07.014. View

3.
Sears M, Radner F . Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respir Med. 2009; 103(12):1960-8. DOI: 10.1016/j.rmed.2009.08.007. View

4.
OByrne P, Bisgaard H, Godard P, Pistolesi M, Palmqvist M, Zhu Y . Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2004; 171(2):129-36. DOI: 10.1164/rccm.200407-884OC. View

5.
Bateman E, Reddel H, Eriksson G, Peterson S, Ostlund O, Sears M . Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol. 2010; 125(3):600-8, 608.e1-608.e6. DOI: 10.1016/j.jaci.2009.11.033. View